Daxor Corp (DE:DX5)
FRANKFURT:DX5
DX5 Stock Chart & Stats
€10.90
€0.30(4.11%)
At close: 4:00 PM EST
€10.90
€0.30(4.11%)
Day’s Range― - ―
52-Week Range€6.20 - €12.60
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
N/A
Enterprise Value€48.63M
Total Cash (Recent Filing)€0.00
Total Debt (Recent Filing)€112.00K
Price to Earnings (P/E)8.0
Beta0.43
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.63
Shares Outstanding5,827,225
10 Day Avg. Volume1
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.60
Price to Sales (P/S)146.07
P/FCF Ratio-121.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€19.46Price Target Upside78.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Validation And AdoptionExtensive clinical validation, peer‑reviewed studies, and new customer wins across diverse medical centers support clinician confidence in the handheld blood volume analyzer and could accelerate clinical adoption.
Commercial Growth And FundingRevenue growth and emerging cash flow, together with a registered financing that provides growth capital, support acceleration of commercialization and scalable market rollout.
Regulatory ExpansionPlanned CLIA waiver submission for moderate‑complexity testing could enable use in non‑CLIA labs and non‑traditional care settings, expanding point‑of‑care access and the addressable market.
Bears Say
Corporate Structure And Valuation DiscountDesignation as a specific investment fund structure may deter some traditional investors and contribute to a persistent valuation discount despite operational progress.
Investment Burn And Profitability PressureOperating division losses driven by heavy research, development, and commercial investment may pressure cash flow and necessitate additional funding before sustainable profitability is reached.
Daxor News
DX5 FAQ
What was Daxor Corp’s price range in the past 12 months?
Daxor Corp lowest stock price was €6.20 and its highest was €12.60 in the past 12 months.
What is Daxor Corp’s market cap?
Currently, no data Available
When is Daxor Corp’s upcoming earnings report date?
Daxor Corp’s upcoming earnings report date is Aug 20, 2026 which is in 140 days.
How were Daxor Corp’s earnings last quarter?
Daxor Corp released its earnings results on Mar 03, 2026. The company reported €1.631 earnings per share for the quarter, beating the consensus estimate of N/A by €1.631.
Is Daxor Corp overvalued?
According to Wall Street analysts Daxor Corp’s price is currently Undervalued.
Does Daxor Corp pay dividends?
Daxor Corp does not currently pay dividends.
What is Daxor Corp’s EPS estimate?
Daxor Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Daxor Corp have?
Daxor Corp has 5,827,225 shares outstanding.
What happened to Daxor Corp’s price movement after its last earnings report?
Daxor Corp reported an EPS of €1.631 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.846%.
Which hedge fund is a major shareholder of Daxor Corp?
Currently, no hedge funds are holding shares in DE:DX5
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Daxor Corp
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.
DX5 Stock 12 Month Forecast
Average Price Target
€19.46
▲(78.53% Upside)
Technical Analysis
Options Prices
Currently, No data available
---